Showing 2,601 - 2,620 results of 6,841 for search '"Japan"', query time: 0.06s Refine Results
  1. 2601
  2. 2602
  3. 2603
  4. 2604
  5. 2605
  6. 2606
  7. 2607
  8. 2608
  9. 2609
  10. 2610
  11. 2611

    Structural validity and internal consistency of the Patient Centred Assessment Method in a primary care setting in a Japanese island area: a cross-sectional study by Masato Matsushima, Shuhei Yoshida, Rieko Mutai, Yoshifumi Sugiyama, Ryoko Horiguchi, Hisashi Yoshimoto

    Published 2022-06-01
    “…Objectives The objective of this study was to examine the structural validity and internal consistency of the original English version of the Patient Centred Assessment Method (PCAM) in a primary care setting in a Japanese island area.Design Cross-sectional study.Setting A clinic on a remote island in Okinawa, Japan, that provides general outpatient and 24-hour emergency services.Participants This study included 355 patients who visited Tarama Clinic from 1 April 2018 to 30 June 2018, were aged ≥20 years, lived in Tarama Village and had decision-making capacity.Main outcome measures Patient complexity scored by the PCAM.Results The mean (SD) PCAM score was 21.4 (5.7). …”
    Get full text
    Article
  12. 2612
  13. 2613
  14. 2614
  15. 2615

    Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study by Mizoguchi Y, Hino M, Ueda H, Miyaguchi Y, Kobayashi M

    Published 2025-01-01
    “…Yoko Mizoguchi,1 Moeko Hino,2 Hitoshi Ueda,3 Yasuo Miyaguchi,3 Masao Kobayashi1,4 1Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; 2Department of Pediatrics, Chiba University Hospital, Chiba, Japan; 3Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 4Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, JapanCorrespondence: Yasuo Miyaguchi, Japan Medical Office, Takeda Pharmaceutical Company Limited, 2 Chome-1-1 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023, Japan, Tel +81 70-4921-7966, Email yasuo.miyaguchi1@takeda.comPurpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. …”
    Get full text
    Article
  16. 2616
  17. 2617
  18. 2618

    Reductions in Muscle Strength and Range of Motion Cause Locomotion Disability via Locomotion-Related Functional Limitation in Japanese Older Adults: A Cross-Sectional Study by Hungu Jung, Shigeharu Tanaka, Yuji Iwamoto, Takashi Kawano, Masahiro Yamasaki, Ryo Tanaka

    Published 2021-01-01
    “…To assess locomotion disability, the locomotor domain of the activities of daily living (ADLs) survey from the Ministry of Education, Culture, Sports, Science, and Technology of Japan was used. Muscle strength (grip strength) and two ROMs (hip flexion and knee flexion) were measured. …”
    Get full text
    Article
  19. 2619
  20. 2620